JD-5006

JD-5006 is a potent, selective, and peripherally restricted small molecule antagonist and inverse agonist of the cannabinoid-1 (CB1) receptor. It was developed as an analog of SLV-319 (Ibipinabant) with modifications to limit its penetration into the brain while maintaining high affinity and selectivity for CB1 over CB2 receptors. JD-5006 exhibits an IC50 of 18 nM for CB1 receptor antagonism and does not significantly inhibit the CB2 receptor (IC50 > 5000 nM). In preclinical studies, it demonstrated minimal brain exposure, supporting its peripheral restriction. Pharmacologically, JD-5006 has shown efficacy in normalizing plasma triglyceride levels, reducing liver mass and ALT levels, improving glycemic control in diabetic models, and enhancing insulin sensitivity. These effects suggest that peripheral blockade of CB1 receptors can yield beneficial metabolic outcomes without central nervous system side effects associated with earlier global CB1 antagonists. The drug is being investigated primarily for metabolic disorders such as obesity, diabetes, dyslipidemia, and liver diseases[1][2][3].